The beneficial effects of T cells unable to shed L-selectin were unrelated to improved recruitment from the bloodstream into tumors or involved LNs but, instead, correlated with early peptide-major histocompatibility complex (MHC) dependent activation of T cells in the tumor microenvironment and in involved lymphoid organs (13). The gene discussed is SELL; the disease is neoplasm.